Andrew M Evens

Summary

Affiliation: Northwestern University
Country: USA

Publications

  1. ncbi A phase II clinical trial of intensive chemotherapy followed by consolidative stem cell transplant: long-term follow-up in newly diagnosed mantle cell lymphoma
    Andrew M Evens
    Robert H Lurie Comprehensive Center of Northwestern University, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
    Br J Haematol 140:385-93. 2008
  2. ncbi Treatment of Hodgkin lymphoma: the past, present, and future
    Andrew M Evens
    Division of Hematology Oncology, Northwestern University Feinberg School of Medicine and the Robert H Lurie Comprehensive Cancer Center, Chicago, IL 60611, USA
    Nat Clin Pract Oncol 5:543-56. 2008
  3. pmc Hypoxia inducible factor-alpha activation in lymphoma and relationship to the thioredoxin family
    Andrew M Evens
    Lymphoma Program, Division of Hematology Oncology, and Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL 60611, USA
    Br J Haematol 141:676-80. 2008
  4. ncbi Motexafin gadolinium induces oxidative stress and apoptosis in hematologic malignancies
    Andrew M Evens
    Division of Hematology Oncology, Northwestern University Feinberg School of Medicine and the Robert H Lurie Comprehensive Cancer Center of Northwestern University, 676 N St Clair, Suite 850, Chicago, IL 60611, USA
    Curr Treat Options Oncol 6:289-96. 2005
  5. pmc The novel expanded porphyrin, motexafin gadolinium, combined with [90Y]ibritumomab tiuxetan for relapsed/refractory non-Hodgkin's lymphoma: preclinical findings and results of a phase I trial
    Andrew M Evens
    Lymphoma Program, Division of Hematology Oncology, The Robert H Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, 676 North St Clair Street, Chicago, IL 60611, USA
    Clin Cancer Res 15:6462-71. 2009
  6. pmc Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports
    A M Evens
    Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
    Ann Oncol 22:1170-80. 2011
  7. pmc Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era
    Andrew M Evens
    DO, MSc, Division of Hematology Oncology, 676 N St Clair S, Suite 850, Chicago, IL, 60611, USA
    J Clin Oncol 28:1038-46. 2010
  8. ncbi Motexafin gadolinium: a redox-active tumor selective agent for the treatment of cancer
    Andrew M Evens
    Division of Hematology Oncology, Northwestern University Feinberg School of Medicine, 676 N St Clair, Chicago, Illinois, IL 60611, USA
    Curr Opin Oncol 16:576-80. 2004
  9. doi Post-transplantation lymphoproliferative disorders: diagnosis, prognosis, and current approaches to therapy
    Andrew M Evens
    Northwestern University Feinberg School of Medicine, Chicago, IL, USA
    Curr Oncol Rep 12:383-94. 2010
  10. ncbi G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis
    Andrew M Evens
    Division of Hematology Oncology, Lymphoma Program, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
    Br J Haematol 137:545-52. 2007

Research Grants

Detail Information

Publications64

  1. ncbi A phase II clinical trial of intensive chemotherapy followed by consolidative stem cell transplant: long-term follow-up in newly diagnosed mantle cell lymphoma
    Andrew M Evens
    Robert H Lurie Comprehensive Center of Northwestern University, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
    Br J Haematol 140:385-93. 2008
    ..001; OS P = 0.0002). CTAP/VMAC induction followed by consolidative auto-HSCT for newly diagnosed MCL is associated with high ORR and durable survival...
  2. ncbi Treatment of Hodgkin lymphoma: the past, present, and future
    Andrew M Evens
    Division of Hematology Oncology, Northwestern University Feinberg School of Medicine and the Robert H Lurie Comprehensive Cancer Center, Chicago, IL 60611, USA
    Nat Clin Pract Oncol 5:543-56. 2008
    ..Furthermore, continued clinical-trial involvement by oncologists and patients is imperative to further advance the field of HL...
  3. pmc Hypoxia inducible factor-alpha activation in lymphoma and relationship to the thioredoxin family
    Andrew M Evens
    Lymphoma Program, Division of Hematology Oncology, and Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL 60611, USA
    Br J Haematol 141:676-80. 2008
    ..g. 44% DLBCL vs. 11% of FL cases with moderate-to-high expression of HIF-1alpha and HIF-2alpha, P = 0.0017). These data demonstrate that HIF and the thioredoxin family are abnormally activated in lymphoma...
  4. ncbi Motexafin gadolinium induces oxidative stress and apoptosis in hematologic malignancies
    Andrew M Evens
    Division of Hematology Oncology, Northwestern University Feinberg School of Medicine and the Robert H Lurie Comprehensive Cancer Center of Northwestern University, 676 N St Clair, Suite 850, Chicago, IL 60611, USA
    Curr Treat Options Oncol 6:289-96. 2005
    ..Various clinical trials studying MGd as a single agent and in combination with radiation and/or chemotherapy for the treatment of hematologic malignancies are ongoing...
  5. pmc The novel expanded porphyrin, motexafin gadolinium, combined with [90Y]ibritumomab tiuxetan for relapsed/refractory non-Hodgkin's lymphoma: preclinical findings and results of a phase I trial
    Andrew M Evens
    Lymphoma Program, Division of Hematology Oncology, The Robert H Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, 676 North St Clair Street, Chicago, IL 60611, USA
    Clin Cancer Res 15:6462-71. 2009
    ..Motexafin gadolinium is a novel anticancer agent that targets redox-dependent pathways and enhances sensitivity of tumor cells to ionizing radiation...
  6. pmc Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports
    A M Evens
    Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
    Ann Oncol 22:1170-80. 2011
    ..Rituximab has been associated with hepatitis B virus reactivation (HBV-R). However, the characteristics and scope of this association remain largely undefined...
  7. pmc Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era
    Andrew M Evens
    DO, MSc, Division of Hematology Oncology, 676 N St Clair S, Suite 850, Chicago, IL, 60611, USA
    J Clin Oncol 28:1038-46. 2010
    ..In addition, clinical factors at diagnosis identified patients with markedly divergent outcomes...
  8. ncbi Motexafin gadolinium: a redox-active tumor selective agent for the treatment of cancer
    Andrew M Evens
    Division of Hematology Oncology, Northwestern University Feinberg School of Medicine, 676 N St Clair, Chicago, Illinois, IL 60611, USA
    Curr Opin Oncol 16:576-80. 2004
    ....
  9. doi Post-transplantation lymphoproliferative disorders: diagnosis, prognosis, and current approaches to therapy
    Andrew M Evens
    Northwestern University Feinberg School of Medicine, Chicago, IL, USA
    Curr Oncol Rep 12:383-94. 2010
    ..Additionally, novel therapeutics, such as adoptive immunotherapy, should continue to be explored...
  10. ncbi G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis
    Andrew M Evens
    Division of Hematology Oncology, Lymphoma Program, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
    Br J Haematol 137:545-52. 2007
    ..0% and OS 91.3% (P = 0.46 and 0.67 respectively). Our experience suggests that ABVD may be safely and effectively administered at >99% dose-intensity without G-CSF support, regardless of the ANC...
  11. ncbi Hodgkin lymphoma in older patients: an uncommon disease in need of study
    Andrew M Evens
    Feinberg School of Medicine, Northwestern University, Robert H Lurie Comprehensive Cancer Center, Chicago, Illinois 60611, USA
    Oncology (Williston Park) 22:1369-79. 2008
    ..Continued multicenter collaborations with prospective clinical trials, including formal assessment of comorbidity and functional status, will be critical to the successful study of elderly HL...
  12. pmc Hypoxia-inducible factor-1 {alpha} expression predicts superior survival in patients with diffuse large B-cell lymphoma treated with R-CHOP
    Andrew M Evens
    DO, Division of Hematology Oncology, 676 N St Clair St, Suite 850, Chicago, IL 60611, USA
    J Clin Oncol 28:1017-24. 2010
    ..CONCLUSION The expression of HIF-1alpha protein is an important independent favorable prognostic factor for survival in patients with DLBCL treated with R-CHOP...
  13. ncbi Sustained hematologic and central nervous system remission with single-agent denileukin diftitox in refractory adult T-cell leukemia/lymphoma
    Andrew M Evens
    Division of Hematology Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, Robert H Lurie Comprehensive Cancer Center, Chicago, IL 60611, USA
    Clin Lymphoma Myeloma 7:472-4. 2007
    ..The patient subsequently underwent matched sibling reduced-intensity allogeneic transplantation and remains disease free. Further study examining denileukin diftitox in patients with relapsed/refractory ATLL is warranted...
  14. ncbi Molecular etiology of mature T-cell non-Hodgkin's lymphomas
    Andrew M Evens
    Division of Hematology Oncology, Department of Medicine, Northwestern University Medical School and The Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL 60611, USA
    Front Biosci 8:d156-75. 2003
    ..Future studies in T-cell NHL are likely to provide additional disease-specific chromosomal translocations and molecular alterations with important translational implications...
  15. doi Bortezomib may be safely combined with Y-90-ibritumomab tiuxetan in patients with relapsed/refractory follicular non-Hodgkin lymphoma: a phase I trial of combined induction therapy and bortezomib consolidation
    Rupali Roy
    Department of Medicine, Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
    Leuk Lymphoma 54:497-502. 2013
    ..5 months (range: 3-22.5+ months). A phase II trial at the MTD is under way to better define the toxicity and effectiveness of this regimen...
  16. pmc Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project
    Charles L Bennett
    MidWest Center for Health Services Research and Policy Studies, VA Chicago Healthcare System, Chicago, IL, USA
    Blood 106:3343-7. 2005
    ..Reinitiation of epoetin therapy among individuals could be considered if antierythropoietin antibodies are undetectable...
  17. pmc Yttrium-90 ibritumomab tiuxetan doses calculated to deliver up to 15 Gy to critical organs may be safely combined with high-dose BEAM and autologous transplantation in relapsed or refractory B-cell non-Hodgkin's lymphoma
    Jane N Winter
    Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
    J Clin Oncol 27:1653-9. 2009
    ....
  18. ncbi Motexafin gadolinium generates reactive oxygen species and induces apoptosis in sensitive and highly resistant multiple myeloma cells
    Andrew M Evens
    Division of Hematology Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, 676 N St Clair, Suite 850, Chicago, IL, 60611, USA
    Blood 105:1265-73. 2005
    ..These studies provide a rationale for clinical investigation of this novel redox-mediating agent in patients with multiple myeloma and related disorders...
  19. pmc PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-kappaB mechanisms and is synergistic with bortezomib in lymphoma cells
    Savita Bhalla
    Division of Hematology Oncology, Northwestern University Feinberg School of Medicine and the Robert H Lurie Comprehensive Cancer Center, Chicago, IL 60611, USA
    Clin Cancer Res 15:3354-65. 2009
    ....
  20. ncbi Haematological malignancies developing in previously healthy individuals who received haematopoietic growth factors: report from the Research on Adverse Drug Events and Reports (RADAR) project
    Charles L Bennett
    VA Midwest Center for Health Services and Policy Research, the Jesse Brown VA Medical Center, Chicago, IL, USA
    Br J Haematol 135:642-50. 2006
    ..While a causal relationship with haematological malignancies cannot be demonstrated, long-term follow-up among healthy individuals who receive haematopoietic growth factors is needed...
  21. ncbi F-18 FDG-PET predicts outcomes for patients receiving total lymphoid irradiation and autologous blood stem-cell transplantation for relapsed and refractory Hodgkin lymphoma
    Ryan D Gentzler
    Division of Hematology Oncology and the Robert H Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
    Br J Haematol 165:793-800. 2014
    ..Achievement of CR with salvage therapy is a powerful predictor of outcome. ..
  22. doi A phase I/II trial of bortezomib combined concurrently with gemcitabine for relapsed or refractory DLBCL and peripheral T-cell lymphomas
    Andrew M Evens
    Division of Hematology Oncology, Tufts University School of Medicine, Boston, MA, USA
    Br J Haematol 163:55-61. 2013
    ..Whereas efficacy of this combination was low in heavily pre-treated DLBCL, there was a signal of activity in relapsed/refractory PTCL utilizing the modified schedule...
  23. doi Analysis of very elderly (≥80 years) non-hodgkin lymphoma: impact of functional status and co-morbidities on outcome
    Chadi Nabhan
    Division of Hematology Oncology, Advocate Lutheran General Hospital, 1700 Luther Lane, Park Ridge, IL, USA
    Br J Haematol 156:196-204. 2012
    ..Prospective studies for very elderly NHL that incorporate geriatric tools, especially ADLs, are warranted...
  24. pmc All trans retinoic acid nanodisks enhance retinoic acid receptor mediated apoptosis and cell cycle arrest in mantle cell lymphoma
    Amareshwar T K Singh
    Division of Haematology Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
    Br J Haematol 150:158-69. 2010
    ..In summary, incorporation of ATRA into ND enhanced the biological activity of this retinoid in cell culture models of MCL...
  25. doi CD23+ mantle cell lymphoma: a clinical pathologic entity associated with superior outcome compared with CD23- disease
    Katalin Kelemen
    Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
    Am J Clin Pathol 130:166-77. 2008
    ..In multivariate Cox regression analysis, CD23 status and leukemic-phase MCL were the most important factors predicting outcome...
  26. ncbi Epoetin-induced pure red-cell aplasia (PRCA): preliminary results from the research on adverse drug events and reports (RADAR) group
    Andrew M Evens
    Divison of Hematology Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine and the Robert H Lurie Comprehensive Cancer Center, Chicago, IL 60611, USA
    Best Pract Res Clin Haematol 18:481-9. 2005
    ..The decrease in cases occurred coincident with these varied changes, although it is difficult to prove causality. PRCA is a rare, but important side effect of epoetin therapy...
  27. ncbi Treatment of T-cell non-Hodgkin's lymphoma
    Andrew M Evens
    Division of Hematology Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine Medical School and the Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL 60611, USA
    Curr Treat Options Oncol 5:289-303. 2004
    ..Prospective multi-institution clinical trials are critically important to determine the most effective treatment regimens that will continue to improve cure rates in these aggressive, yet treatable and often curable, diseases...
  28. ncbi Oxidative stress and apoptosis: a new treatment paradigm in cancer
    Ryan H Engel
    Division of Hematology Oncology, Northwestern University Feinberg School of Medicine, The Robert H Lurie Comprehensive Cancer Center, Chicago, IL 60611, USA
    Front Biosci 11:300-12. 2006
    ..Continued research is needed to better understand the mechanisms and specific apoptotic pathways involved in ROS-induced cell death, as well as, to determine the most rationale and effective combination of redox-active agents...
  29. pmc Mitochondrial-mediated apoptosis in lymphoma cells by the diterpenoid lactone andrographolide, the active component of Andrographis paniculata
    Shuo Yang
    Department of Medicine, Northwestern University Feinberg School of Medicine, Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, USA
    Clin Cancer Res 16:4755-68. 2010
    ..Furthermore, it has been shown to inhibit cancer cell proliferation and induce apoptosis in leukemia and solid tumor cell lines...
  30. doi Pemetrexed in the treatment of relapsed/refractory primary central nervous system lymphoma
    Jeffrey J Raizer
    Northwestern University, Feinberg School of Medicine, 710 North Lake Shore Drive, Chicago, IL 60611, USA
    Cancer 118:3743-8. 2012
    ..Because methotrexate is an integral part of PCSNL treatment, the authors assessed the antitumor activity and safety of pemetrexed in recurrent PCNSL...
  31. ncbi Motexafin gadolinium enhances p53-Mdm2 interactions, reducing p53 and downstream targets in lymphoma cell lines
    Amareshwar T K Singh
    Division of Hematology Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL 60611, USA
    Anticancer Res 30:1131-6. 2010
    ..We hypothesized that reactive oxygen species (ROS)-generating MGd results in low-level p53 expression, making cells more susceptible to oxidant stress...
  32. ncbi Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project
    June M McKoy
    Division of Geriatric Medicine, Department of Medicine, Feinberg School of Medicine, Northwestern University, 303 E Chicago, Chicago, IL 60611, USA
    Leuk Res 31:599-604. 2007
    ....
  33. doi Dietary factors and risk of t(14;18)-defined subgroups of non-Hodgkin lymphoma
    Brian C H Chiu
    Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, 680 North Lake Shore Drive, Suite 1102, Chicago, IL 60611 4402, USA
    Cancer Causes Control 19:859-67. 2008
    ....
  34. ncbi The potential of arsenic trioxide in the treatment of malignant disease: past, present, and future
    Andrew M Evens
    Department of Medicine, Divison of Hematology Oncology, Northwestern University, Feinberg School of Medicine, Robert H Lurie Comprehensive Cancer Center, 676 N St Clair, Suite 850, Chicago, IL 60611, USA
    Leuk Res 28:891-900. 2004
    ..Continued study of As2O3 as a single-agent and in combination therapy will allow identification of the safest and most effective treatment regimens for malignant disease...
  35. ncbi Relapsed and refractory Hodgkin lymphoma: transplantation strategies and novel therapeutic options
    Kevin A David
    Division of Hematology Oncology, The Robert H Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
    Curr Treat Options Oncol 8:352-74. 2007
    ..Continued translational and collaborative prospective clinical research efforts are needed in order to continue to increase the survival rates for Hodgkin lymphoma and to lessen the toxicities associated with lymphoma-related therapy...
  36. ncbi Sun exposure and non-Hodgkin lymphoma: a population-based, case-control study
    Lori K Soni
    Department of Preventive Medicine, Northwestern University Medical School, Chicago, IL, United States
    Eur J Cancer 43:2388-95. 2007
    ..In conclusion, our data suggest that total hours of sun exposure is associated with a lower risk of NHL, and the inverse association is not modified by vitamin D intake, is stronger among farmer, and may vary by subtypes...
  37. ncbi Clinical characteristics of erythropoietin-associated pure red cell aplasia
    Kenneth R Carson
    Division of Hematology Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine and the Robert H Lurie Comprehensive Cancer Center, Chicago, IL, USA
    Best Pract Res Clin Haematol 18:467-72. 2005
    ..Timely identification and treatment of this rare syndrome can prevent the development of severe red blood cell transfusion requirements and the potential complications of iron overload, which results from these transfusions...
  38. pmc Vaccination history and risk of non-Hodgkin lymphoma: a population-based, case-control study
    Heather A Lankes
    Department of Preventive Medicine, Feinberg School of Medicine, Northwestern University, 680 North Lake Shore Drive, Suite 1102, Chicago, IL 60611 4402, USA
    Cancer Causes Control 20:517-23. 2009
    ..Results of few epidemiologic studies conducted thus far are inconsistent, and only one has examined the association by histologic subtype...
  39. ncbi Radioimmunotherapy in non-Hodgkin's lymphoma: trials of yttrium 90-labeled ibritumomab tiuxetan and beyond
    Andrew M Evens
    Division of Hematology Oncology, Feinberg School of Medicine and the Robert H Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA
    Clin Lymphoma 5:S11-5. 2004
    ..Radioimmunotherapy represents a safe and effective treatment modality for patients with NHL...
  40. doi Post-transplant lymphoproliferative disease (PTLD): risk factors, diagnosis, and current treatment strategies
    Zeina Al-Mansour
    Division of Hematology Oncology, The University of Massachusetts Medical School, Worcester, 01568, USA
    Curr Hematol Malig Rep 8:173-83. 2013
    ..Finally, novel treatment strategies for PTLD have emerged, including adoptive immunotherapy and rational targeted therapeutics (e.g., anti-CD30 based therapy and downstream signaling pathways of latent membrane protein-2A)...
  41. pmc Pre-diagnosis cigarette smoking and overall survival in non-Hodgkin lymphoma
    Nicholas J Ollberding
    Division of Biostatistics and Epidemiology, Cincinnati Children s Hospital Medical Center, Cincinnati, OH, USA Department of Health Studies, University of Chicago, Chicago, IL, USA
    Br J Haematol 163:352-6. 2013
    ..The inferior survival was more pronounced for follicular than for diffuse large B cell lymphoma. Pre-diagnosis cigarette smoking may adversely impact the survival of NHL patients. ..
  42. ncbi A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era
    Andrew M Evens
    Division of Hematology Oncology, University of Massachusetts Medical School, Worcester, 01655, USA
    Blood 119:692-5. 2012
    ..04). Furthermore, a novel survival model based on number of these risk factors (0, 1, or 2) showed differential 2-year OS of 83%, 70%, and 13%, respectively (P < .0001) and 5-year OS of 73%, 51%, and 0%, respectively (P < .0001)...
  43. doi Clinical, morphologic, immunophenotypic, and molecular cytogenetic assessment of CD4-/CD8-γδ T-cell large granular lymphocytic leukemia
    Yi Hua Chen
    Dept of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
    Am J Clin Pathol 136:289-99. 2011
    ..Awareness of these features is important for early recognition and accurate diagnosis of patients with CD4-/CD8- γδ T-LGL leukemia...
  44. pmc The novel anti-MEK small molecule AZD6244 induces BIM-dependent and AKT-independent apoptosis in diffuse large B-cell lymphoma
    Savita Bhalla
    Department of Medicine, Division of Hematology Oncology, Northwestern University Feinberg School of Medicine and the Robert H Lurie Comprehensive Cancer Center, Chicago, IL, USA
    Blood 118:1052-61. 2011
    ..Altogether, these findings show that the novel anti-MEK agent, AZD6244, induced apoptosis in DLBCL and that cell death was BIM-dependent...
  45. ncbi T-cell non-Hodgkin lymphoma
    Mujahid A Rizvi
    Division of Hematology Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, 676 N St Clair St, Ste 850, Chicago, IL 60611, USA
    Blood 107:1255-64. 2006
    ..Additional studies are required to learn more about the biology of these diseases, which may lead to more optimal and possibly targeted therapies...
  46. ncbi Frontline bortezomib and rituximab for the treatment of newly diagnosed high tumour burden indolent non-Hodgkin lymphoma: a multicentre phase II study
    Andrew M Evens
    Division of Hematology Oncology, Tufts Medical Center, Boston, MA, USA
    Br J Haematol 166:514-20. 2014
    ..Collectively, bortezomib/rituximab is a non-cytotoxic therapeutic regimen that was well tolerated and resulted in long-term survival rates approximating prior rituximab/cytotoxic chemotherapy series for untreated HTB FL. ..
  47. ncbi The impact of race, age, and sex in follicular lymphoma: A comprehensive SEER analysis across consecutive treatment eras
    Chadi Nabhan
    Section of Hematology and Oncology, Department of Medicine, The University of Chicago, Chicago, Illinois
    Am J Hematol 89:633-8. 2014
    ....
  48. pmc Paradoxical regulation of hypoxia inducible factor-1α (HIF-1α) by histone deacetylase inhibitor in diffuse large B-cell lymphoma
    Savita Bhalla
    Department of Medicine, Division of Hematology Oncology Northwestern University Feinberg School of Medicine and the Robert H Lurie Comprehensive Cancer Center, Chicago, Illinois, United States of America
    PLoS ONE 8:e81333. 2013
    ....
  49. ncbi Imexon-induced apoptosis in multiple myeloma tumor cells is caspase-8 dependent
    Andrew M Evens
    Departments of Medicine and Pathology, Feinberg School of Medicine and the Robert H Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois 60611, USA
    Clin Cancer Res 10:1481-91. 2004
    ..We examined the mechanism of imexon cytotoxicity in a diverse panel of dexamethasone and chemotherapy-sensitive and -resistant myeloma cell lines...
  50. ncbi The Research on Adverse Drug Events and Reports (RADAR) project
    Charles L Bennett
    Jesse Brown VA Medical Center Mid West Center for Health Services and Policy Research, Chicago, Ill 60611, USA
    JAMA 293:2131-40. 2005
    ....
  51. ncbi Burkitt's and Burkitt-like lymphoma
    Andrew M Evens
    Division of Hematology Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine Medical School and the Robert H Lurie Comprehensive Cancer Center of Northwestern University, 676 N St Clair, Suite 850, Chicago, IL 60611, USA
    Curr Treat Options Oncol 3:291-305. 2002
    ..Clinical trials remain critical to determine the most effective treatment regimens that will continue to improve cure rates in this aggressive but treatable disease...
  52. ncbi Primary cutaneous and systemic anaplastic large cell lymphoma: clinicopathologic aspects and therapeutic options
    Christiane Querfeld
    Section of Dermatology, University of Chicago, Chicago, Illinois, USA
    Oncology (Williston Park) 24:574-87. 2010
    ..Continued clinical trial involvement by oncologists and patients is imperative to improve the outcomes for this malignancy...
  53. doi Radioimmunotherapy for the treatment of non-Hodgkin lymphoma: current status and future applications
    Sairah Ahmed
    Division of Hematology Oncology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
    Leuk Lymphoma 51:1163-77. 2010
    ..A reappraisal of prior data and examination of recently published and ongoing studies will be important in recognizing the potential benefit of RIT in the treatment of NHL...
  54. doi Chemotherapeutic advancements in peripheral T-cell lymphoma
    Nishitha M Reddy
    Division of Hematology Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN Electronic address
    Semin Hematol 51:17-24. 2014
    ..In order to improve outcomes for PTCL, it remains critical to consider these patients for clinical studies. In this article, we examine the recent progress and changing landscape of treatment of PTCL...
  55. doi Lymphoma occurring during pregnancy: antenatal therapy, complications, and maternal survival in a multicenter analysis
    Andrew M Evens
    Andrew M Evens, Tufts University School of Medicine, Boston Aimee Kroll Desrosiers, University of Massachusetts Medical School, Worcester, MA Ranjana Advani and Stavroula Otis, Stanford University Medical Center, Stanford, CA Oliver W Press and Linda M Parker, Fred Hutchinson Cancer Research Center, Seattle, WA Izidore S Lossos, Liat Nadav Dagan, and Jose Sandoval, University of Miami School of Medicine, Miami, FL Julie M Vose, University of Nebraska Medical Center, Omaha, NE Francisco J Hernandez Ilizaliturri, Roswell Park Cancer Institute, Buffalo Ramsey Abdallah and John P Leonard, Weill Cornell Medical College, New York, NY Barrett K Robinson, Indiana University School of Medicine, Indianapolis, IN Jessica L Yarber and Leo I Gordon, Northwestern University Feinberg School of Medicine, Chicago, IL Kristie A Blum, The Ohio State University, Columbus, OH Christopher R Flowers, Emory University, Atlanta, GA Thomas M Habermann, Mayo Clinic, Rochester, MN and Nancy L Bartlett, Washington University School of Medicine, St Louis, MO
    J Clin Oncol 31:4132-9. 2013
    ..Lymphoma is the fourth most frequent cancer in pregnancy; however, current clinical practice is based largely on small series and case reports...
  56. ncbi Pure red-cell aplasia and epoetin therapy
    Charles L Bennett
    MidWest Center for Health Services Research and Policy Studies, Jesse Brown Veterans Affairs Medical Center, Chicago, IL 60611, USA
    N Engl J Med 351:1403-8. 2004
    ....
  57. doi Dietary intake of fruit and vegetables and risk of non-Hodgkin lymphoma
    Brian C H Chiu
    Department of Health Studies, University of Chicago, 5841 South Maryland Avenue, MC 2007, Chicago, IL 60637, USA
    Cancer Causes Control 22:1183-95. 2011
    ..Few studies have evaluated the potential association between consumption of fruit and vegetables and non-Hodgkin lymphoma (NHL) by histologic subtype, and the results of these studies have been inconsistent...
  58. pmc Primary mediastinal large B-cell lymphoma in HIV: report of two cases
    Katalin Kelemen
    Department of Pathology, Northwestern Memorial Hospital, Northwestern University Feinberg School of Medicine, 251 E Huron Street, Feinberg 7 302, Chicago, IL, 60611, USA
    J Hematop 2:45-9. 2009
    ..The second patient, a 38-year-old male with disseminated disease, responded to therapy and is disease-free after 9 months of follow-up...
  59. ncbi T-cell non-Hogdkin's lymphoma
    Andrew M Evens
    Department of Medicine, Division of Hematology Oncology Northwestern University Feinberg School of Medicine and the Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL 60611, USA
    Cancer Treat Res 131:161-220. 2006
  60. ncbi Targeting angiogenesis for the treatment of sarcoma
    Lakshmi Balasubramanian
    Northwestern University Feinberg School of Medicine and the Robert H Lurie Comprehensive Cancer Center, Chicago, Illinois 60611, USA
    Curr Opin Oncol 18:354-9. 2006
    ..Preclinical studies have demonstrated the anti-tumor effects of varied anti-angiogenic agents in sarcoma cell lines and tumor models...
  61. ncbi Multiple successful desensitizations to brentuximab vedotin: a case report and literature review
    Michael D DeVita
    From the aDepartment of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois bDivision of Hematology Oncology, Tufts University School of Medicine, Tufts Medical Center, Boston, Massachusetts and cDivision of Hematology Oncology, Northwestern University Feinberg School of Medicine, dRobert H Lurie Comprehensive Cancer Center of Northwestern University, and eDivision of Allergy Immunology, Northwestern University Feinberg School of Medicine, Chicago, Illinois
    J Natl Compr Canc Netw 12:465-71. 2014
    ..With progressive dose titration and supportive care, the patient tolerated this therapy. She received 11 doses through a rapid desensitization protocol and experienced a durable disease remission. ..
  62. ncbi Obesity and risk of non-Hodgkin lymphoma (United States)
    Brian C H Chiu
    Department of Preventive Medicine, Feinberg School of Medicine, Northwestern University, 680 North Lake Shore Drive, Suite 1102, Chicago, IL 60611 4402, USA
    Cancer Causes Control 18:677-85. 2007
    ....
  63. ncbi TTP/HUS occurring in a simultaneous pancreas/kidney transplant recipient after clopidogrel treatment: evidence of a nonimmunological etiology
    Andrew M Evens
    Department of Internal Medicine Oncology Hematology, Lakeside VA, Chicago, IL 60611, USA
    Transplantation 74:885-7. 2002
    ..We present a second case of TTP/HUS developing in an SPK recipient who was also receiving clopidogrel...
  64. doi The challenges of epidemiologic research in non-Hodgkin lymphoma
    Andrew M Evens
    JAMA 300:2059-61. 2008

Research Grants2

  1. Targeting the Mitochondria to Treat Lymphoma and Myeloma
    Andrew Evens; Fiscal Year: 2007
    ..These investigations will be significant, as they are expected to provide a new target for the treatment of hematologic malignancies and will advance the fundamental understanding of oxidative stress and apoptosis. ..